Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors

Journal of Experimental Medicine

Volumn 209, Issue 13, 2012, Pages 2351-2365

  Ni, Jing ^a   Miller, Matthias ^a   Stojanovic, Ana ^a   Garbi, Natalio ^a,b   Cerwenka, Adelheid ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR ALPHA;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL ACTIVITY; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; INNATE IMMUNITY; IRRADIATION; LYMPHOCYTE FUNCTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADAPTIVE IMMUNITY; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-15; INTERLEUKIN-18; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; SPLEEN; TIME FACTORS;

EID: 84872225254     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20120944     Document Type: Article

References (60)

1. Bachanova, V., L.J. Burns, D.H. McKenna, J. Curtsinger, A. Panoskaltsis-Mortari, B.R. Lindgren, S. Cooley, D. Weisdorf, and J.S. Miller. 2010. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol. Immunother. 59:1739-1744. http://dx.doi.org/10.1007/s00262-010-0896-z
2. Bihl, F., J. Pecheur, B. Bréart, G. Poupon, J. Cazareth, V. Julia, N. Glaichenhaus, and V.M. Braud. 2010. Primed antigen-specific CD4+ T cells are required for NK cell activation in vivo upon Leishmania major infection. J. Immunol. 185:2174-2181. http://dx.doi.org/10.4049/jimmunol.1001486
3. Cerwenka, A. 2009. New twist on the regulation of NKG2D ligand ex-pression. J. Exp. Med. 206:265-268. http://dx.doi.org/10.1084/jem.20090225
4. Cerwenka, A., and L.L. Lanier. 2001. Natural killer cells, viruses and cancer. Nat. Rev. Immunol. 1:41-49. http://dx.doi.org/10.1038/35095564
5. Coca, S., J. Perez-Piqueras, D. Martinez, A. Colmenarejo, M.A. Saez, C. Vallejo, J.A. Martos, and M. Moreno. 1997. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 79:2320-2328. http://dx.doi.org/10.1002/(SICI)1097-0142 (19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P
6. Cooper, M.A., J.M. Elliott, P.A. Keyel, L. Yang, J.A. Carrero, and W.M.Yokoyama. 2009. Cytokine-induced memory-like natural killer cells. Proc. Natl. Acad. Sci. USA. 106:1915-1919. http://dx.doi.org/10.1073/pnas.0813192106
7. Corthay, A., D.K. Skovseth, K.U. Lundin, E. Røsjø, H. Omholt, P.O. Hofgaard, G. Haraldsen, and B. Bogen. 2005. Primary antitumor im- mune response mediated by CD4+ T cells. Immunity. 22:371-383. http://dx.doi.org/10.1016/j.immuni.2005.02.003
8. D'Urso, C.M., Z.G. Wang, Y. Cao, R. Tatake, R.A. Zeff, and S. Ferrone. 1991. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J. Clin. Invest. 87: 284-292. http://dx.doi.org/10.1172/JCI114984
9. Dudley, M.E., J.R. Wunderlich, P.F. Robbins, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R. Sherry, N.P. Restifo, A.M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854. http://dx.doi.org/10.1126/science.1076514
10. Dudley, M.E., J.C. Yang, R. Sherry, M.S. Hughes, R. Royal, U. Kammula, P.F. Robbins, J. Huang, D.E. Citrin, S.F. Leitman, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of inten-sive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26:5233-5239. http://dx.doi.org/10.1200/JCO.2008.16.5449
11. Fehniger, T.A., M.A. Cooper, G.J. Nuovo, M. Cella, F. Facchetti, M. Colonna, and M.A. Caligiuri. 2003. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 101:3052-3057. http://dx.doi.org/10.1182/blood-2002-09-2876
12. Galani, I.E., M. Wendel, A. Stojanovic, M. Jesiak, M.M. Müller, C. Schellack, E. Suri-Payer, and A. Cerwenka. 2010. Regulatory T cells control mac- rophage accumulation and activation in lymphoma. Int. J. Cancer. 127: 1131-1140. http://dx.doi.org/10.1002/ijc.25132
13. Ganss, R., E. Ryschich, E. Klar, B. Arnold, and G.J. Hämmerling. 2002. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62:1462-1470.
14. Garbi, N., B. Arnold, S. Gordon, G.J. Hämmerling, and R. Ganss. 2004. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172:5861-5869.
15. Gasser, S., S. Orsulic, E.J. Brown, and D.H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 436:1186-1190. http://dx.doi.org/10.1038/nature03884
16. + T cells. J. Exp. Med. 202:907-912. http://dx.doi.org/10.1084/jem.20050732
17. Gattinoni, L., D.J. Powell Jr., S.A. Rosenberg, and N.P. Restifo. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6:383-393. http://dx.doi.org/10.1038/nri1842
18. Geller, M.A., and J.S. Miller. 2011. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy. 3:1445-1459. http://dx.doi.org/10.2217/ imt.11.131
19. Geller, M.A., S. Cooley, P.L. Judson, R. Ghebre, L.F. Carson, P.A. Argenta, A.L. Jonson, A. Panoskaltsis-Mortari, J. Curtsinger, D. McKenna, et al. 2011. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 13:98-107. http://dx.doi.org/10.3109/14653249.2010.515582
20. He, X.S., M. Draghi, K. Mahmood, T.H. Holmes, G.W. Kemble, C.L. Dekker, A.M. Arvin, P. Parham, and H.B. Greenberg. 2004. T celldependent production of IFN-gamma by NK cells in response to influenza A virus. J. Clin. Invest. 114:1812-1819.
21. Hochweller, K., J. Striegler, G.J. Hämmerling, and N. Garbi. 2008. A novel CD11c. DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur. J. Immunol. 38:2776-2783. http://dx.doi.org/10.1002/eji.200838659
22. Horowitz, A., K.C. Newman, J.H. Evans, D.S. Korbel, D.M. Davis, and E.M. Riley. 2010. Cross-talk between T cells and NK cells generates rapid effector responses to Plasmodium falciparum-infected erythrocytes. J. Immunol. 184:6043-6052. http://dx.doi.org/10.4049/jimmunol.1000106
23. Imai, K., S. Matsuyama, S. Miyake, K. Suga, and K. Nakachi. 2000. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 356:1795-1799. http://dx.doi.org/10.1016/S0140-6736(00)03231-1
24. Jamieson, A.M., P. Isnard, J.R. Dorfman, M.C. Coles, and D.H. Raulet. 2004. Turnover and proliferation of NK cells in steady state and lymphopenic conditions. J. Immunol. 172:864-870.
25. Kärre, K., H.G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 319:675-678. http://dx.doi.org/10.1038/319675a0
26. Lee, S.H., M.F. Fragoso, and C.A. Biron. 2012. Cutting Edge: A novel mechanism bridging innate and adaptive immunity: IL-12 induction of CD25 to form high-affinity IL-2 receptors on NK cells. J. Immunol. 189:2712-2716. http://dx.doi.org/10.4049/jimmunol.1201528
27. Li, Z., F. Pradera, T. Kammertoens, B. Li, S. Liu, and Z. Qin. 2007. Cross-talk between T cells and innate immune cells is crucial for IFN- gamma-dependent tumor rejection. J. Immunol. 179:1568-1576.
28. Ljunggren, H.G., and K.J. Malmberg. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7:329-339. http://dx.doi.org/10.1038/nri2073
29. Martín-Fontecha, A., L.L. Thomsen, S. Brett, C. Gerard, M. Lipp, A. Lanzavecchia, and F. Sallusto. 2004. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 5:1260-1265. http://dx.doi.org/10.1038/ni1138
30. Miller, J.S., Y. Soignier, A. Panoskaltsis-Mortari, S.A. McNearney, G.H. Yun, S.K. Fautsch, D. McKenna, C. Le, T.E. Defor, L.J. Burns, et al. 2005. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 105:3051-3057. http://dx.doi.org/10.1182/blood-2004-07-2974
31. Moretta, L., F. Locatelli, D. Pende, E. Marcenaro, M.C. Mingari, and A. Moretta. 2011. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 117:764-771. http://dx.doi.org/10.1182/blood-2010-08-264085
32. Muranski, P., A. Boni, C. Wrzesinski, D.E. Citrin, S.A. Rosenberg, R. Childs, and N.P. Restifo. 2006. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat. Clin. Pract. Oncol. 3:668-681. http://dx.doi.org/10.1038/ncponc0666
33. O'Leary, J.G., M. Goodarzi, D.L. Drayton, and U.H. von Andrian. 2006.T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat. Immunol. 7:507-516. http://dx.doi.org/10.1038/ni1332
34. Pandiyan, P., L. Zheng, S. Ishihara, J. Reed, and M.J. Lenardo. 2007.CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 8:1353-1362. http://dx.doi.org/10.1038/ni1536
35. Parkhurst, M.R., J.P. Riley, M.E. Dudley, and S.A. Rosenberg. 2011. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17:6287-6297. http://dx.doi.org/10.1158/1078-0432.CCR-11-1347
36. Passweg, J.R., A. Tichelli, S. Meyer-Monard, D. Heim, M. Stern, T. Kühne, G. Favre, and A. Gratwohl. 2004. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 18:1835-1838. http://dx.doi.org/10.1038/sj.leu.2403524
37. Paust, S., and U.H. von Andrian. 2011. Natural killer cell memory. Nat. Immunol. 12:500-508. http://dx.doi.org/10.1038/ni.2032
38. Pegram, H.J., N.M. Haynes, M.J. Smyth, M.H. Kershaw, and P.K. Darcy. 2010. Characterizing the anti-tumor function of adoptively transferred NK cells in vivo. Cancer Immunol. Immunother. 59:1235-1246. http:// dx.doi.org/10.1007/s00262-010-0848-7
39. Pegram, H.J., D.M. Andrews, M.J. Smyth, P.K. Darcy, and M.H. Kershaw. 2011. Activating and inhibitory receptors of natural killer cells. Immunol. Cell Biol. 89:216-224. http://dx.doi.org/10.1038/icb.2010.78
40. Perez-Diez, A., N.T. Joncker, K. Choi, W.F. Chan, C.C. Anderson, O. Lantz, and P. Matzinger. 2007. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 109:5346-5354. http://dx.doi.org/10.1182/blood-2006-10-051318
41. Qin, Z., J. Schwartzkopff, F. Pradera, T. Kammertoens, B. Seliger, H. Pircher, and T. Blankenstein. 2003. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 63:4095-4100.
42. Quezada, S.A., K.S. Peggs, T.R. Simpson, Y. Shen, D.R. Littman, and J.P. Allison. 2008. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205:2125-2138. http://dx.doi.org/10.1084/jem.20080099
43. + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207:637-650. http://dx.doi.org/10.1084/jem.20091918
44. Raulet, D.H., and N. Guerra. 2009. Oncogenic stress sensed by the im-mune system: role of natural killer cell receptors. Nat. Rev. Immunol. 9:568-580. http://dx.doi.org/10.1038/nri2604
45. Romee, R., S.E. Schneider, J.W. Leong, J.M. Chase, C.R. Keppel, R.P. Sullivan, M.A. Cooper, and T.A. Fehniger. 2012. Cytokine activation induces human memory-like NK cells. Blood. http://dx.doi.org/10.1182/blood-2012-04-419283
46. Rosenberg, S.A., M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Matory, J.M. Skibber, E. Shiloni, J.T. Vetto, et al. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313:1485-1492. http://dx.doi.org/10.1056/NEJM198512053132327
47. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W.D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 295:2097-2100. http://dx.doi.org/10.1126/science.1068440
48. Salagianni, M., E. Lekka, A. Moustaki, E.G. Iliopoulou, C.N. Baxevanis, M. Papamichail, and S.A. Perez. 2011. NK cell adoptive transfer com- bined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J. Immunol. 186:3327-3335. http://dx.doi.org/10.4049/jimmunol.1000652
49. Sun, J.C., J.N. Beilke, and L.L. Lanier. 2009a. Adaptive immune features of natural killer cells. Nature. 457:557-561. http://dx.doi.org/10.1038/nature07665
50. Sun, J.C., A. Ma, and L.L. Lanier. 2009b. Cutting edge: IL-15-independent NK cell response to mouse cytomegalovirus infection. J. Immunol. 183:2911-2914. http://dx.doi.org/10.4049/jimmunol.0901872
51. Sun, J.C., S. Lopez-Verges, C.C. Kim, J.L. DeRisi, and L.L. Lanier. 2011. NK cells and immune "memory". J. Immunol. 186:1891-1897. http://dx.doi.org/10.4049/jimmunol.1003035
52. Terme, M., E. Ullrich, N.F. Delahaye, N. Chaput, and L. Zitvogel. 2008.Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 9:486-494. http://dx.doi.org/10.1038/ni1580
53. van den Broek, M.F., D. Kägi, R.M. Zinkernagel, and H. Hengartner. 1995. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur. J. Immunol. 25:3514-3516. http://dx.doi.org/10.1002/eji.1830251246
54. Villegas, F.R., S. Coca, V.G. Villarrubia, R. Jiménez, M.J. Chillón, J. Jareño, M. Zuil, and L. Callol. 2002. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 35:23-28. http://dx.doi.org/10.1016/S0169-5002(01)00292-6
55. Vivier, E., E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini. 2008. Functions of natural killer cells. Nat. Immunol. 9:503-510. http://dx.doi.org/10.1038/ni1582
56. Vivier, E., D.H. Raulet, A. Moretta, M.A. Caligiuri, L. Zitvogel, L.L. Lanier, W.M. Yokoyama, and S. Ugolini. 2011. Innate or adaptive immunity? The example of natural killer cells. Science. 331:44-49. http://dx.doi.org/10.1126/science.1198687
57. Wendel, M., I.E. Galani, E. Suri-Payer, and A. Cerwenka. 2008. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 68:8437-8445. http://dx.doi.org/10.1158/0008-5472.CAN-08-1440
58. Wiesel, M., and A. Oxenius. 2012. From crucial to negligible: functional CD8+ T-cell responses and their dependence on CD4+ T-cell help. Eur. J. Immunol. 42:1080-1088. http://dx.doi.org/10.1002/eji.201142205
59. + T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207:651-667. http://dx.doi.org/10.1084/jem.20091921
60. Zingoni, A., T. Sornasse, B.G. Cocks, Y. Tanaka, A. Santoni, and L.L. Lanier. 2004. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J. Immunol. 173:3716-3724.